Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 206932, held by ABHAI. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 206932 (Methylphenidate Hydrochloride), held by ABHAI, was first approved by FDA on May 11, 2017, with 3 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults Narcolepsy Methylphenidate hydrochloride tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2017 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Jul 17, 2026 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jun 3, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters